Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-759,633
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
L-759,633 is a small molecule cannabinoid agonist being developed by Immugen BioPharma as a non-hormonal treatment for genitourinary syndrome of menopause (GSM). It is a non-psychoactive derivative of tetrahydrocannabinol (THC) that selectively targets the peripheral cannabinoid type 2 (CB2) receptor with approximately 163-fold selectivity over the CB1 receptor. By activating CB2 receptors highly expressed in vaginal tissue, L-759,633 aims to restore tissue thickness, improve structural integrity and barrier function, and restore glycogen expression to support a healthy microbiome. The compound is currently in preclinical development for conditions associated with GSM, including vulvovaginal atrophy, sexual dysfunction, and urinary (bladder) dysfunction.
- Other names
- non-psychoactive THC derivative
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on L-759,633.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-759,633.